Nab-paclitaxel plus anti-PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).
被引:0
作者:
Li, Xiaofen
论文数: 0引用数: 0
h-index: 0
机构:Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
Li, Xiaofen
Zhou, Nan
论文数: 0引用数: 0
h-index: 0
机构:Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
Zhou, Nan
Yang, Yu
论文数: 0引用数: 0
h-index: 0
机构:Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
Yang, Yu
Gou, Hongfeng
论文数: 0引用数: 0
h-index: 0
机构:Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
Gou, Hongfeng
机构:
[1] Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Med Oncol,Gastr Canc Ctr, Chengdu, Peoples R China